Drug intelligence / Profile preview

NVP-NK4146

Development stage: Unknown
Lead developer: NVP Healthcare
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

NVP-NK4146 is an orally administered microbiome-based therapeutic candidate being developed by NVP Healthcare (Navipharm) for the treatment of mild cognitive impairment (MCI) associated with Alzheimer's disease. As a live biotherapeutic product, NVP-NK4146 is designed to modulate the gut-brain axis, a complex communication network between the gastrointestinal tract and the central nervous system, to potentially improve cognitive function and reduce neuroinflammation. The drug is currently undergoing clinical evaluation, including a 36-week randomized, double-blind, placebo-controlled trial to assess its safety and efficacy in patients with MCI due to Alzheimer's disease. It is also entering Phase 1 clinical trials in the United States.

Beyond the preview

Go deeper on NVP-NK4146.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NVP-NK4146.

Explore the full profile